Status:

COMPLETED

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Lead Sponsor:

U.S. Army Medical Research and Development Command

Collaborating Sponsors:

Walter Reed Army Institute of Research (WRAIR)

Conditions:

Meningitis, Meningococcal, Serogroup B

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to determine if the vaccine called Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is safe and free from side effects and if it will protect people from meningitis. This ...

Detailed Description

Meningococcal disease is a contagious bacterial disease caused by Neisseria meningitidis that can kill children and young adults very quickly. Meningococci are divided into distinct sergroups based on...

Eligibility Criteria

Inclusion

  • Healthy military or civilian males or non-pregnant, non-lactating females
  • Age 18-45
  • Give informed consent and understand risk and benefit of study
  • Understands and willing to comply with all protocol procedures and time commitment
  • FEMALES only: surgically sterilized or received a negative pregnancy test on day of first injection AND agrees to practice adequate birth control, if necessary, for the next 7 months after first vaccination.

Exclusion

  • Currently has or has had a history of significant organ/system disease
  • History of allergy to any vaccine
  • Allergy to component of vaccine such as aluminum hydroxide
  • Presence of significant unexplained laboratory abnormality
  • HIV sero-positive or any other immunosuppressive state
  • Positive test for HBsAg, or hepatitis C
  • Ongoing drug abuse/dependence
  • Received any live vaccine, experimental products or immunosuppressive therapy in the last 28 days or inactivated vaccine in the past 14 days, or received parenteral immunoglobulin or blood products within the past 3 months
  • Intention to leave study area for an extended period of time during the study
  • Females: positive urine pregnancy test prior to vaccination

Key Trial Info

Start Date :

December 5 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2007

Estimated Enrollment :

34 Patients enrolled

Trial Details

Trial ID

NCT00248833

Start Date

December 5 2005

End Date

December 1 2007

Last Update

October 29 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Walter Reed Army Institute of Research, Clinical Trials Center

Silver Spring, Maryland, United States, 20910